JTCS Click here to go to SJM website.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Robert E. Stroud
Francis G. Spinale
John S. Ikonomidis
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barbour, J. R.
Right arrow Articles by Ikonomidis, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barbour, J. R.
Right arrow Articles by Ikonomidis, J. S.

J Thorac Cardiovasc Surg 2006;132:788-795
© 2006 The American Association for Thoracic Surgery

Surgery for Acquired Cardiovascular Disease

Temporal disparity in the induction of matrix metalloproteinases and tissue inhibitors of metalloproteinases after thoracic aortic aneurysm formation

John R. Barbour, MDa, Robert E. Stroud, MSa, Abigail S. Lowry, BSa, Leslie L. Clark, MSa, Allyson M. Leone, BSa, Jeffery A. Jones, PhDa, Francis G. Spinale, MD, PhDa,b, John S. Ikonomidis, MD, PhDa,*

a Cardiothoracic Surgical Research, Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC
b Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC.

Received for publication January 29, 2006; revisions received May 11, 2006; accepted for publication May 22, 2006.

* Address for reprints: John S. Ikonomidis, MD, PhD, Division of Cardiothoracic Surgery, Medical University of South Carolina, Suite 409 CSB, 96 Jonathan Lucas St, Charleston, SC 29425. (Email: ikonomij{at}musc.edu).

Background: An important component of matrix remodeling during thoracic aortic aneurysm progression is the balance between matrix metalloproteinases and their endogenous inhibitors (tissue inhibitors of metalloproteinases). However, whether and to what degree matrix metalloproteinase/tissue inhibitor of metalloproteinases profiles change over time with an evolving thoracic aortic aneurysm remains unclear.

Methods: Descending thoracic aortic aneurysms were induced in mice (FVB strain, 15 minutes of 0.5 mol/L CaCl2 exposure) and followed for 24 hours, 72 hours, 1 week, 2 weeks, 4 weeks, or 8 weeks (each group, n = 13). Thoracic aortic aneurysm size was determined by means of video micrometry, and immunoblotting was used to measure aortic matrix metalloproteinase 2, 8, 9, and 12 and tissue inhibitor of metalloproteinases 1 and 4 levels (expressed as a percentage of control values, n = 13).

Results: Increased aortic diameter was detected by 72 hours and reached a maximal size at 4 weeks (135% ± 4% increase from baseline, P < .05), which is consistent with thoracic aortic aneurysm progression. Active matrix metalloproteinase 8 (collagenase) levels increased at 72 hours (178% ± 49%, P < .05 from control), and active matrix metalloproteinase 12 (elastase) levels increased by 24 hours (138% ± 11%, P < .05), whereas active matrix metalloproteinase 2 levels increased at 72 hours and 1 week after thoracic aortic aneurysm induction (72 hours: 158% ± 12%, 1 week: 162% ± 19%; P < .05). At 1 week after thoracic aortic aneurysm induction, active matrix metalloproteinase 9 and 12 levels decrease (matrix metalloproteinase 9: 55% ± 5%; matrix metalloproteinase 12: 63% ± 5%; P < .05); however, matrix metalloproteinase 9 and 12 levels were increased from these values at 4 and 8 weeks (P < .05). Tissue inhibitor of metalloproteinases 1 levels were decreased at 1 week (52% ± 15%, P < .05) and later returned to control values, whereas tissue inhibitor of metalloproteinases 4 levels increased at the late thoracic aortic aneurysm time points (4 weeks: 278% ± 46%; 8 weeks: 213% ± 40%; P < .05).

Conclusions: These findings show 2 phases of matrix metalloproteinase abundance during murine thoracic aortic aneurysm formation. The late tissue inhibitor of metalloproteinases 4 increase might explain prevention of further aortic dilation past 4 weeks. Unique matrix metalloproteinase/tissue inhibitor of metalloproteinases temporal relationships occurred during the natural history of thoracic aortic aneurysm progression that might hold both diagnostic and therapeutic relevance.

Abbreviations and Acronyms ECM = extracellular matrix; MMP = matrix metalloproteinase; TAA = thoracic aortic aneurysm; TIMP = tissue inhibitor of metalloproteinases




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
J. A. Jones, C. Beck, J. R. Barbour, J. A. Zavadzkas, R. Mukherjee, F. G. Spinale, and J. S. Ikonomidis
Alterations in Aortic Cellular Constituents during Thoracic Aortic Aneurysm Development: Myofibroblast-Mediated Vascular Remodeling
Am. J. Pathol., October 1, 2009; 175(4): 1746 - 1756.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
J. M. Ruddy, J. A. Jones, F. G. Spinale, and J. S. Ikonomidis
Regional heterogeneity within the aorta: Relevance to aneurysm disease.
J. Thorac. Cardiovasc. Surg., November 1, 2008; 136(5): 1123 - 1130.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. Monaco, P. Stassano, L. Di Tommaso, and G. Iannelli
Response of plasma matrix metalloproteinases and tissue inhibitor of metalloproteinases to stent-graft surgery for descending thoracic aortic aneurysms.
J. Thorac. Cardiovasc. Surg., October 1, 2007; 134(4): 925 - 931.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The American Association for Thoracic Surgery.